{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:08:31Z","timestamp":1793405311750,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40263-026-01316-6","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:59:53Z","timestamp":1784293193000},"page":"1259-1283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Disease Stabilization with MEK Inhibitors in NF1-Associated Plexiform Neurofibromas: A Systematic Review and Meta-Analysis with Subgroup Analyses by Age and Study Design"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3637-5033","authenticated-orcid":false,"given":"Sai","family":"Sanikommu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro N.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashar M.","family":"Dawoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo J.","family":"Komotar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"1","key":"1316_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02911-2","volume":"18","author":"TJ Lee","year":"2023","unstructured":"Lee TJ, Chopra M, Kim RH, Parkin PC, Barnett-Tapia C. Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis. Orphanet J Rare Dis. 2023;18(1):292. https:\/\/doi.org\/10.1186\/s13023-023-02911-2.","journal-title":"Orphanet J Rare Dis"},{"key":"1316_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.4","volume":"3","author":"DH Gutmann","year":"2017","unstructured":"Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Primers. 2017;3:17004. https:\/\/doi.org\/10.1038\/nrdp.2017.4.","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"1316_CR3","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1093\/neuonc\/noac146","volume":"24","author":"MJ Fisher","year":"2022","unstructured":"Fisher MJ, Blakeley JO, Weiss BD, et al. Management of neurofibromatosis type 1-associated plexiform neurofibromas. Neuro Oncol. 2022;24(11):1827\u201344. https:\/\/doi.org\/10.1093\/neuonc\/noac146.","journal-title":"Neuro Oncol"},{"issue":"3","key":"1316_CR4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jpeds.2011.08.051","volume":"160","author":"CE Prada","year":"2012","unstructured":"Prada CE, Rangwala FA, Martin LJ, et al. Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1. J Pediatr. 2012;160(3):461\u20137. https:\/\/doi.org\/10.1016\/j.jpeds.2011.08.051.","journal-title":"J Pediatr"},{"issue":"8","key":"1316_CR5","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/s1474-4422(14)70063-8","volume":"13","author":"AC Hirbe","year":"2014","unstructured":"Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13(8):834\u201343. https:\/\/doi.org\/10.1016\/s1474-4422(14)70063-8.","journal-title":"Lancet Neurol"},{"issue":"15","key":"1316_CR6","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020;382(15):1430\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1912735.","journal-title":"N Engl J Med"},{"key":"1316_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-7-75","volume":"7","author":"R Nguyen","year":"2012","unstructured":"Nguyen R, Dombi E, Widemann BC, et al. Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1. Orphanet J Rare Dis. 2012;7:75. https:\/\/doi.org\/10.1186\/1750-1172-7-75.","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"1316_CR8","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1093\/neuonc\/noac109","volume":"24","author":"AM Gross","year":"2022","unstructured":"Gross AM, Glassberg B, Wolters PL, et al. Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity. Neuro Oncol. 2022;24(11):1978\u201388. https:\/\/doi.org\/10.1093\/neuonc\/noac109.","journal-title":"Neuro Oncol"},{"issue":"26","key":"1316_CR9","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"Dombi E, Baldwin A, Marcus LJ, et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med. 2016;375(26):2550\u201360. https:\/\/doi.org\/10.1056\/NEJMoa1605943.","journal-title":"N Engl J Med"},{"issue":"1","key":"1316_CR10","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1172\/jci60578","volume":"123","author":"WJ Jessen","year":"2013","unstructured":"Jessen WJ, Miller SJ, Jousma E, et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest. 2013;123(1):340\u20137. https:\/\/doi.org\/10.1172\/jci60578.","journal-title":"J Clin Invest"},{"issue":"7","key":"1316_CR11","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1200\/jco.20.02220","volume":"39","author":"BD Weiss","year":"2021","unstructured":"Weiss BD, Wolters PL, Plotkin SR, et al. NF106: a Neurofibromatosis Clinical Trials Consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas. J Clin Oncol. 2021;39(7):797\u2013806. https:\/\/doi.org\/10.1200\/jco.20.02220.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1316_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11523-022-00888-9","volume":"17","author":"T Trippett","year":"2022","unstructured":"Trippett T, Toledano H, Campbell Hewson Q, et al. Cobimetinib in pediatric and young adult patients with relapsed or refractory solid tumors (iMATRIX-cobi): a multicenter, phase I\/II study. Target Oncol. 2022;17(3):283\u201393. https:\/\/doi.org\/10.1007\/s11523-022-00888-9.","journal-title":"Target Oncol"},{"issue":"10496","key":"1316_CR13","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/s0140-6736(25)00986-9","volume":"405","author":"AP Chen","year":"2025","unstructured":"Chen AP, Coyne GO, Wolters PL, et al. Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study. Lancet. 2025;405(10496):2217\u201330. https:\/\/doi.org\/10.1016\/s0140-6736(25)00986-9.","journal-title":"Lancet"},{"issue":"10","key":"1316_CR14","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1158\/1078-0432.Ccr-25-3291","volume":"32","author":"Z Wang","year":"2026","unstructured":"Wang Z, Huang J, Liu J, et al. Efficacy and safety of tunlametinib in adults with inoperable neurofibromatosis type 1-associated plexiform neurofibromas: phase IIa trial and biomarker research. Clin Cancer Res. 2026;32(10):1934\u201345. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-25-3291.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1316_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02927-2","volume":"21","author":"X Hu","year":"2023","unstructured":"Hu X, Li W, Zeng K, et al. Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas. BMC Med. 2023;21(1):230. https:\/\/doi.org\/10.1186\/s12916-023-02927-2.","journal-title":"BMC Med"},{"issue":"6","key":"1316_CR16","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1200\/jco.24.01034","volume":"43","author":"CL Moertel","year":"2025","unstructured":"Moertel CL, Hirbe AC, Shuhaiber HH, et al. ReNeu: a pivotal, phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma. J Clin Oncol. 2025;43(6):716\u201329. https:\/\/doi.org\/10.1200\/jco.24.01034.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1316_CR17","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1093\/neuonc\/noae121","volume":"26","author":"H Kim","year":"2024","unstructured":"Kim H, Yoon HM, Kim EK, et al. Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma. Neuro Oncol. 2024;26(12):2352\u201363. https:\/\/doi.org\/10.1093\/neuonc\/noae121.","journal-title":"Neuro Oncol"},{"issue":"1","key":"1316_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41591-024-03361-4","volume":"31","author":"AM Gross","year":"2025","unstructured":"Gross AM, O\u2019Sullivan Coyne G, Dombi E, et al. Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial. Nat Med. 2025;31(1):105\u201315. https:\/\/doi.org\/10.1038\/s41591-024-03361-4.","journal-title":"Nat Med"},{"issue":"1","key":"1316_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaa095","volume":"2","author":"S Jackson","year":"2020","unstructured":"Jackson S, Baker EH, Gross AM, et al. The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas. Neuro-oncol Adv. 2020;2(1):vdaa095. https:\/\/doi.org\/10.1093\/noajnl\/vdaa095.","journal-title":"Neuro-oncol Adv"},{"issue":"1","key":"1316_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdad054","volume":"5","author":"S Suenobu","year":"2023","unstructured":"Suenobu S, Terashima K, Akiyama M, et al. Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: an open-label, phase I study. Neuro-oncol Adv. 2023;5(1):vdad054. https:\/\/doi.org\/10.1093\/noajnl\/vdad054.","journal-title":"Neuro-oncol Adv"},{"issue":"1","key":"1316_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/ana.78010","volume":"99","author":"DC Noordhoek","year":"2026","unstructured":"Noordhoek DC, Hanff DF, French PJ, et al. Trametinib in adults with neurofibromatosis type 1-related symptomatic plexiform neurofibromas. Ann Neurol. 2026;99(1):73\u201383. https:\/\/doi.org\/10.1002\/ana.78010.","journal-title":"Ann Neurol"},{"issue":"1","key":"1316_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdae177","volume":"6","author":"J Passos","year":"2024","unstructured":"Passos J, Soares MP, Salgado D, et al. A single-center case study series assessing the effect of selumetinib use in patients with neurofibromatosis-related plexiform neurofibromas. Neuro-oncol Adv. 2024;6(1):vdae177. https:\/\/doi.org\/10.1093\/noajnl\/vdae177.","journal-title":"Neuro-oncol Adv"},{"issue":"3","key":"1316_CR23","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s11060-025-05197-5","volume":"175","author":"C Santoro","year":"2025","unstructured":"Santoro C, Servedio M, Diana MC, et al. Real-world experience with selumetinib in children with neurofibromatosis type 1: a multicentric retrospective study. J Neurooncol. 2025;175(3):1027\u201337. https:\/\/doi.org\/10.1007\/s11060-025-05197-5.","journal-title":"J Neurooncol"},{"key":"1316_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/10732748221144930","volume":"30","author":"A Cacchione","year":"2023","unstructured":"Cacchione A, Fabozzi F, Carai A, et al. Safety and efficacy of MEK inhibitors in the treatment of plexiform neurofibromas: a retrospective study. Cancer Control. 2023;30:10732748221144930. https:\/\/doi.org\/10.1177\/10732748221144930.","journal-title":"Cancer Control"},{"issue":"2","key":"1316_CR25","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s11060-020-03443-6","volume":"147","author":"V Esp\u00edrito Santo","year":"2020","unstructured":"Esp\u00edrito Santo V, Passos J, Nzwalo H, et al. Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience. J Neurooncol. 2020;147(2):459\u201363. https:\/\/doi.org\/10.1007\/s11060-020-03443-6.","journal-title":"J Neurooncol"},{"issue":"8","key":"1316_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29633","volume":"69","author":"H Coltin","year":"2022","unstructured":"Coltin H, Perreault S, Larouche V, et al. Selumetinib for symptomatic, inoperable plexiform neurofibromas in children with neurofibromatosis type 1: a national real-world case series. Pediatr Blood Cancer. 2022;69(8):e29633. https:\/\/doi.org\/10.1002\/pbc.29633.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"1316_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2025.103438","volume":"153","author":"P Boitez","year":"2025","unstructured":"Boitez P, Farges D, Descamps M, Bournazel V, Martin L. The first year of treatment with selumetinib for NF1-related plexiform neurofibroma is medically challenging in real-life settings. Ann Dermatol Venereol. 2025;153(1):103438. https:\/\/doi.org\/10.1016\/j.annder.2025.103438.","journal-title":"Ann Dermatol Venereol"},{"issue":"4","key":"1316_CR28","doi-asserted-by":"publisher","first-page":"328","DOI":"10.5114\/polp.2025.156337","volume":"100","author":"J Styczy\u0144ska","year":"2025","unstructured":"Styczy\u0144ska J, Marja\u0144ska A, Jatczak-Gaca A, et al. Therapy with selumetinib in children with neurofibromatosis type 1 in Poland: clinical experience of the first year of the national program. Pediatr Pol. 2025;100(4):328\u201331. https:\/\/doi.org\/10.5114\/polp.2025.156337.","journal-title":"Pediatr Pol"},{"key":"1316_CR29","volume-title":"Cochrane handbook for systematic reviews of interventions","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane handbook for systematic reviews of interventions. 2nd ed. Chichester: Wiley; 2019.","edition":"2nd ed"},{"key":"1316_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"issue":"5","key":"1316_CR31","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrc3911","volume":"15","author":"N Ratner","year":"2015","unstructured":"Ratner N, Miller SJ. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer. 2015;15(5):290\u2013301. https:\/\/doi.org\/10.1038\/nrc3911.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1316_CR32","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1172\/jci63193","volume":"123","author":"T Chang","year":"2013","unstructured":"Chang T, Krisman K, Theobald EH, et al. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. J Clin Invest. 2013;123(1):335\u20139. https:\/\/doi.org\/10.1172\/jci63193.","journal-title":"J Clin Invest"},{"issue":"9","key":"1316_CR33","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1002\/ajmg.a.37123","volume":"167a","author":"PL Wolters","year":"2015","unstructured":"Wolters PL, Burns KM, Martin S, et al. Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life. Am J Med Genet A. 2015;167a(9):2103\u201313. https:\/\/doi.org\/10.1002\/ajmg.a.37123.","journal-title":"Am J Med Genet A"},{"issue":"21 Suppl. 1","key":"1316_CR34","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1212\/01.wnl.0000435747.02780.bf","volume":"81","author":"PL Wolters","year":"2013","unstructured":"Wolters PL, Martin S, Merker VL, et al. Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials. Neurology. 2013;81(21 Suppl. 1):S6-14. https:\/\/doi.org\/10.1212\/01.wnl.0000435747.02780.bf.","journal-title":"Neurology"},{"issue":"2","key":"1316_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-025-05419-w","volume":"176","author":"S Sanikommu","year":"2026","unstructured":"Sanikommu S, Santos AN, Wipplinger C, Dawoud B, Komotar RJ, Lu VM. Patient-reported outcomes as prognostic indicators for overall survival and progression-free survival in brain tumor patients: a systematic review and meta-analysis of randomized clinical trials. J Neurooncol. 2026;176(2):154. https:\/\/doi.org\/10.1007\/s11060-025-05419-w.","journal-title":"J Neurooncol"},{"issue":"10","key":"1316_CR36","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/neuonc\/noad086","volume":"25","author":"AM Gross","year":"2023","unstructured":"Gross AM, Dombi E, Wolters PL, et al. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1\/2 trial for inoperable plexiform neurofibromas. Neuro Oncol. 2023;25(10):1883\u201394. https:\/\/doi.org\/10.1093\/neuonc\/noad086.","journal-title":"Neuro Oncol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01316-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01316-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01316-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:01:30Z","timestamp":1786993290000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01316-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1316"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01316-6","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"12 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Sai Sanikommu, Alejandro N. Santos, Bashar M. Dawoud, Adam S. Levy, Ricardo J. Komotar, and Victor M. Lu have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study does not require ethics approval.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Coda availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Concept and design: SS, VML, RJK. Literature review: SS, BD, ANS, ASL. Data collection: SS, BD, ANS, ASL. Analysis: SS. Writing and editing: SS, VML, RJK, ANS. Reviewing: all authors.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}